Table 2 GI50 (µM) of oxindole–benzothiazole hybrid 9o on NCI cancer cell lines
Cell name | 9o GI50 (µM) | Cell name | 9o GI50 (µM) |
|---|---|---|---|
Leukemia | M14 | 47.4 | |
CCRF-CEM | 6.08 | MDA-MB-435 | 20.6 |
HL-60 (TB) | > 100 | SK-MEL-2 | > 100 |
K-562 | 3.75 | SK-MEL-28 | > 100 |
MOLT-4 | 5.05 | SK-MEL-5 | 41.5 |
RPMI-8226 | 61.4 | UACC-257 | > 100 |
SR | 20.9 | UACC-62 | 59.3 |
Non-small cell lung cancer | Ovarian cancer | ||
A549/ATCC | 30.9 | IGROV1 | 2.22 |
EKVX | 20.0 | OVCAR-3 | 2.49 |
HOP-62 | 7.84 | OVCAR-4 | > 100 |
HOP-92 | 51.9 | OVCAR-5 | > 100 |
NCI-H226 | 21.3 | OVCAR-8 | 4.02 |
NCI-H23 | 3.03 | NCI/ADR-RES | 18.5 |
NCI-H322M | > 100 | SK-OV-3 | 48.9 |
NCI-H460 | 9.26 | Renal cancer | |
NCI-H522 | 48.0 | 786-0 | 16.1 |
Colon cancer | A498 | > 100 | |
COLO 205 | 10.6 | ACHN | 6.70 |
HCC-2998 | 5.34 | CAKI-1 | 56.2 |
HCT-116 | 4.50 | RXF 393 | 5.06 |
HCT-15 | 3.60 | SN12C | 25.6 |
HT29 | 26.8 | TK-10 | 71.7 |
KM12 | > 100 | UO-31 | 2.03 |
SW-620 | 2.27 | Prostate cancer | |
CNS cancer | PC-3 | 3.78 | |
SF-268 | > 100 | DU-145 | 2.92 |
SF-295 | 11.8 | Breast cancer | |
SF-539 | 39.9 | MCF7 | 3.44 |
SNB-19 | 5.72 | MDA-MB-231/ATCC | 5.44 |
SNB-75 | nda | HS 578T | 24.8 |
U251 | 2.02 | BT-549 | 17.6 |
Melanoma | T-47D | 41.0 | |
LOX IMVI | 4.09 | MDA-MB-468 | 3.72 |
MALME-3M | 2.28 |